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ABSTRACT: The new platinum(II) complexes cis-[Pt(sac)2(NH3)2] (sac = saccharinate) and 
cis-[Pt(tsac)2(NH3)2] (tsac = thiosaccharinate) have been prepared, the X-ray crystal structure 
of cis-[Pt(sac)2(NH3)2].H2O reveals that both saccharinate anions are N-bound in a cis-
arrangement being inequivalent in both the solid-state and in solution at room temperature. 
Preliminary anti-cancer activity has been assessed against A549 human alveolar type-II like 
cell lines with the thiosaccharinate complex showing good activity.   
Keywords: cisplatin, ammine, saccharinate, thiosaccharinate, X-ray structure, anti-cancer  
A key feature of cisplatin activity [1-7] is the slow displacement of one chloride by water, 
which in turn is readily displaced by a range of nucleic bases, most commonly guanine [8-12] 
and then crosslink DNA via displacement of the second chloride [13-18]. Due primarily to its 
widespread use of saccharin (sacH) as an artificial sweetener, the coordination chemistry of 
the saccharinate anion (sac) has been extensively studied [19]. While it is capable of binding 
to transition metals in a number of different ways, by far the most common is the simple N-
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bound coordination [19]. This mode of binding is observed exclusively at four-coordinate 
platinum(II) and palladium(II) centres [20-27]. Most pertinent to the work described herein 
are pyridine (py) and substituted pyridine adducts, cis-[Pt(sac)2(py)2], prepared upon addition 
of sodium saccharinate to the relevant dichlorides [20]. This behavior is different to that 
noted for [PtCl2(
2
-dppf)] [dppf = bis(diphenylphosphino)ferrocene], which even under 
forcing conditions adds only a single equivalent of saccharinate to afford [PtCl(sac)(2-dppf)] 
[27]. Given the importance of both cisplatin and saccharin we were surprised to find that the 
interaction of the two had not to be noted in the literature. Herein we report that saccharinate 
readily displaces both chlorides of cisplatin to afford cis-[Pt(sac)2(NH3)2] (1) which has been 
crystallographically characterized and give preliminary details of its anti-cancer activity 
together with that of the related thiosaccharinate (tsac) complex, cis-[Pt(tsac)2(NH3)2] (2), 
which we postulate contains a PtN2S2 core. 
Cis-[Pt(sac)2(NH3)2] (1) was obtained as colorless crystals upon treatment of cisplatin with 
two equivalents of sodium saccharinate in boiling water
1
. It is soluble in dimethylformamide 
(DMF) and DMSO, but insoluble in other common organic solvents. For comparison the 
related thiosaccharinate (tsac) complex cis-[Pt(tsac)2(NH3)2] (2) was prepared
2
 (Scheme 1). It 
shows far greater solubility in common organic solvents, believed to be a result of the binding 
of this ligand through sulfur [19,27]. The facile formation of 2 is somewhat surprising as 
                                           
1 Synthesis and characterization of cis-[Pt(sac)2(NH3)2].H2O (1.H2O) - A solution of sodium 
saccharinate (0.27 g, 1.33 mmol) in hot water (10 cm
3
) was added to a solution of cis-
[PtCl2(NH3)2] (0.20 g, 0.667 mmol) in hot water (10 cm
3
). The mixture was refluxed for 
1 h. The colorless-white crystals formed were filtered off and dried in vacuo. Yield: 85% 
(0.33 g). Anal. Calcd. for C14H16N4O7PtS2: C, 27.50; H, 2.64; N, 9.16. Found: C, 27.60; 
H, 2.60; N, 9.22%. IR (KBr) (ν, cm-1): 3524s, 3298s, 3277s, 3134s, 1693s, 1666s, 1585s, 
1462m, 1285s, 1246s, 1169s, 978s, 795m, 565m. 
1
H NMR (d
7
-DMF): 8.09-8.05 (m, 1H), 
7.99-7.93 (m, 2H), 7.91-7.87 (m, 1H), 4.78 (brs, 1 H), 4.56 and 4.52 (brs, 5H). 
13
C{
1
H} 
NMR (d
7
-DMF): 165.6, 164.9, 142.0, 141.8, 133.1, 132.8, 132.8, 132.6, 131.9, 131.6, 
123.2, 123.1, 119.8, 119.5 ppm. Positive mode ESI-FTICR m/z 594.007284 [M+H], 
calcd for [C14H15N4O6PtS2]
+
 594.007284.  
 
2
 Synthesis and characterization of cis-[Pt(tsac)2(NH3)2] (2) - A solution of thiosaccharinate 
(0.26g, 1.33 mmol) in hot water (30 cm
3
) was added to a solution of cis-[PtCl2(NH3)2] (0.20 
g, 0.667 mmol) in hot water (15 cm
3
). The mixture was refluxed for 2 h. The light-brown 
solid formed was filtered off washed several times with distilled water and dried in vacuo. 
Yield: 89% (0.39 g). Anal. Calcd. for C14H14N4O4PtS4: C, 26.88; H, 2.26; N, 8.96. Found: C, 
26.33; H, 2.09; N, 8.86%. IR (KBr) (ν, cm-1): 3471m, 3413m, 3286m, 1627s, 1440w, 1373s, 
1315s, 1236m, 1155m, 1126s, 1008w, 817s, 515m. 
1
H NMR (d
6
-DMSO): 7.96-7.90 (m, 4H), 
7.82-7.75 (m, 4H), 4.54 (s, 6 H). 
13
C{
1
H} NMR (d
6
-DMSO): 182.8, 137.6, 133.7, 133.4, 
133.1, 124.3, 120.7 ppm. 
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reactions of cisplatin with thiols generally result in loss of ammonia rather [28-31]. 
Formation of 1-2 probably results from direct attack of the saccharinate or thiosaccharinate 
anions on cisplatin [32,33] since it is known that aquation of cisplatin is slow [13-18]. 
A crystallographic study of 1 (which crystallizes with a molecule of water) was carried out
3
 
(Figure 1). The Pt-N1 and Pt-N2 bond distances 2.042(4) and 2.018(4) Å are similar to other 
Pt(II)-saccharinate complexes [19-27]. The Pt-N3 and Pt-N4 distances of 2.044(4) and 
2.065(4) Å compare well with those of 2.05(4) and 1.95(3) Å in cisplatin [34] and also 
related Pt(II)-ammine complexes [35-38]. The saccharinate ligands are inequivalent in the 
solid-state and adopt a relative anti-arrangement and each is twisted with respect to the PtN4 
plane, by 52.1
o
 for the ligand containing N(1) and 87.6
o
 for N(2). A similar arrangement is 
seen in related species of the type cis-[Pt(NH3)2(nucleobase)2]
2+
 as probed by 
crystallographic [35] and NMR [40] studies. For example in cis-[Pt(NH3)2(9-
methyladenine)(9-ethylguanine)][NO3]2·2H2O [37], the nucleobases adopt a relative syn-
arrangement being rotated by 66.07 and 88.26
o
 respectively with respect to the PtN4 plane. 
The asymmetric unit contains a molecule of water which sits in the cleft made by the two 
saccharinate ligands. One of the protons on the water has a short contact with O(3) from an 
SO2 group of the N(1) saccharinate ligand [O(3)…H(15) 1.970 Å]. The same oxygen atom 
also has a relatively short intramolecular contact with the nitrogen atom of the second 
saccharinate group [O(3)…N(2) 2.928 Å; sum of van der Waals radii: 3.05 Å].  
NMR spectra for 1 are more complex than expected for a simple cis-MX2L2 system, with 
broad signals at  4.78, 4.56, 4.52 (in d7-DMF) and  4.79, 4.69 (in d6-DMSO) seen in the 1H 
NMR spectrum for the NH3 protons. In comparison, the NH3 resonances in cisplatin appear 
as a singlet at  4.06 in H2O/D2O [40], although a more complex spectrum is observed in 
DMSO [41]. At 80 
o
C in DMSO the broad ammonia resonances collapse into the baseline and 
by 120 
o
C no amine resonances could be detected. Upon cooling the sample back to room 
temperature amine resonances were still absent and we conclude that amine substitution (by 
DMSO) has occurred. Complex 2 shows good solubility in a range of organic solvents, 
attributed to the S-bound coordination of the thiosaccharinate ligand [19]. Spectroscopic data 
                                           
3
 Crystallographic Data: white block, size 0.50  0.30  0.12 mm, monoclinic, space group 
P21/c, a = 12.642(1) Å, b = 9.7435(8) Å, c = 14.786(1) Å,  = 90.59(1)
o
, V = 1821.2(3) 
Å
3
, Z = 4, dcalc = 2.230 g/cm
3
,  mm-1, F(000) = 1176, unique refns.(Rint) 3559 
(0.0536), R (I ≥ 2σ(I), R1 = 0.025, wR2  = 0.045, R (all data) R1 = 0.042, wR2 = 0.049. 
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are in accord with a symmetrical MX2L2 species: in the 
1
H NMR spectrum, the six NH3 
protons appear as a singlet at  4.54. In the absence of a crystallographic study we cannot 
unequivocally deduce the regioselectivity but strongly favour a relative cis arrangement of 
ligands.    
We have undertaken preliminary anti-cancer activity studies [42] on both complexes against 
A549 human alveolar type-II cell lines
4
 and using methotrexate as a positive control and an 
MTT assay was used to determine their dose-dependent cytotoxicity
5
 after 24 and 48 h 
(Figure 2). These show that 2 has higher activity than 1 and the activity of the former at 
higher concentrations (100 g/ml and 250 g/ml) is significantly greater than the control at 
these concentrations. Reasons for this are not clear, but it is well-known that a significant 
amount of cisplatin is hydrolysed outside of the cell and renally excreted upon binding to 
plasma proteins, and thus only ca. 10% binds to DNA. It may be that the strong Pt-S bond 
results in more of the complex penetrating into the cell and becoming DNA bound. An 
alternative explanation is that the trans labilization of thiolates leads to a quite different 
mechanism of action in which ammine loss may be significant [28-31]. It is somewhat 
surprising that cis-[Pt(SR)2(NH3)2] complexes remain elusive given the strength of the Pt-S 
interaction. Indeed sulfur-coordinating ligands are potential “rescue agents” or “protecting 
agents” providing competition with methionine and cysteine residues in proteins to reduce 
adverse binding thereby diminishing toxic side effects [29]. With this in mind we are 
                                           
4 Human alveolar type-II (ATII)-like cell lines A549 were cultured in Dulbecco’s Modified 
Eagle Medium (DMEM) with L-Glutamine (Lonza, Switzerland) supplemented with 
10% (v/v) FCS (Lonza, Switzerland), Penicillin (10000 U/mL) and Streptomycin (10000 
U/mL) (Lonza, Switzerland). Cells were cultivated in 75 cm
2
 tissue culture flasks and 
maintained under standard cell culture conditions (5.0% CO2, 95% humidity and 37°C in 
incubators). Cells were passaged twice per week. 
 
5
 A 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay was used to 
determine dose-dependent cytotoxicity with Methotrexate as a positive control. Cells were 
seeded out in 96-well-tissue plates (Sarstedt, USA) with a volume of 200 µL. Cultivation 
took 3 days at 37 °C, 5.0% CO2 and 100% humidity. After cultivation wells were grown until 
reaching confluence. A-549 cells were washed once in PBS and treated with the samples (1 
and 2) and Methotrexate from 12.5 to 240 µg/mL concentrations for 24 and 48 h. Samples 
were then removed completely and cells were incubated in 110 µL/well, 10% MTT solution 
(5.0 mg/mL PBS) in supplement-free medium for 4 h. With this incubation time the formazan 
complex was produced inside the cells. To release the purple salt, 100 µL SDS solution (1.0 g 
SDS in 10 mL 0.01 M HCl) were added per well and after 24 h of incubation, the UV-vis 
absorption was measured at 570 nm with 630 nm as reference wavelength using a micro-plate 
reader. 
 5 
currently further exploring the cytotoxicity of 2 together with that of related Pt(II)-
thiosaccharinate complexes. 
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Captions for figures 
Figure 1. The molecular structure of cis-[Pt(sac)2(NH3)2].H2O (1).H2O with selected bond 
lengths (Å) and angles (
o
): Pt-N(1) 2.042(4), Pt-N(2) 2.018(4), Pt-N(3) 2.044(4), Pt-N(4) 
2.065(4), O(3)..N(2) 2.928, O(3)…H(15) 1.970, N(1)-Pt-N(2) 92.5(1), N(3)-Pt-N(4) 93.0(2), 
N(1)-Pt-N(3) 178.0(2), N(2)-Pt-N(4) 178.0(2), O(2)...H(13) 2.370, O(2)...H(12) 2.947, 
O(1)...H(19) 2.653, O(1)...H(10) 2.644, O(5)...H(16) 1.947 
Figure 2. Dose dependent cytotoxicity of cis-[Pt(sac)2(NH3)2] (1) (denoted A) and cis-
[Pt(tsac)2(NH3)2] (2) (denoted B) on a A549 cell line after 24 h (red-dark) and 48 h (green-
light) incubation periods. 
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Figure 1 
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Scheme 1 
 
